Amedisys, Inc. (NASDAQ:AMED) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Amedisys, Inc. (NASDAQ:AMED) by 1.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,298 shares of the health services provider’s stock after acquiring an additional 1,412 shares during the quarter. Rhumbline Advisers owned 0.28% of Amedisys worth $8,289,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. National Bank of Canada FI grew its stake in shares of Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after purchasing an additional 30,213 shares in the last quarter. ABC Arbitrage SA acquired a new stake in Amedisys in the fourth quarter worth about $2,522,000. Geode Capital Management LLC grew its position in Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after buying an additional 7,071 shares in the last quarter. Quarry LP acquired a new position in Amedisys during the 3rd quarter valued at about $2,569,000. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after buying an additional 9,004 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Up 1.2 %

AMED stock opened at $91.54 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. The firm has a market cap of $3.00 billion, a PE ratio of 36.33, a P/E/G ratio of 1.80 and a beta of 0.73. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The firm has a 50 day simple moving average of $90.85 and a 200 day simple moving average of $93.32.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a report on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Amedisys presently has an average rating of “Hold” and an average price target of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.